Replimune Announces Positive Initial Data from the Anti-PD1 …
Dec 7, 2022 · The IGNYTE clinical trial is evaluating RP1 (vusolimogene oderparepvec) in combination with nivolumab, with the anti-PD1 failed melanoma cohort being conducted with registrational intent.
Michigan EDM scene cuts ties with Chad Smith and Ignyte Events ...
Jul 30, 2024 · The Oakland County Jail confirmed that Chad Smith, who is also known as “DJ Attak” and served as president of music company Ignyte Events, was detained Sunday and released Monday on domestic...
Replimune Presents Primary Analysis Data from IGNYTE Clinical …
Sep 15, 2024 · Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance to...
Replimune Announces Late-Breaking Abstract of IGNYTE Clinical …
WOBURN, Mass., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that a late-breaking abstract presenting the primary analysis of the IGNYTE clinical trial has been selected for oral presentation ...
RP1/Nivolumab Combo Shows Durable Responses, Favorable …
Sep 15, 2024 · A confirmatory phase 3 trial, IGNYTE-3 (NCT06264180), is actively recruiting patients to further evaluate RP1 plus nivolumab in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4. The study will compare RP1 plus nivolumab with physician’s choice of therapy.
Efficacy and safety of RP1 combined with nivolumab in patients …
May 29, 2024 · Here, we present data from pts with anti–PD-1–failed melanoma, including the initial cohort and updated data from a registration-directed (R-D) cohort, from the phase 1/2 IGNYTE study (NCT03767348).
Company News - Ignyte
Here, you can find the latest news and important happenings at Ignyte. We'll keep you up-to-date on our new ideas, big achievements, and what's going on in our industry.
Ignyte Acquisition Corp. Stockholders Approve Proposed Business ...
Oct 27, 2022 · Ignyte Acquisition Corp. (“Ignyte”) (NASDAQ: IGNY), a publicly traded special purpose acquisition company, today announced that Ignyte’s stockholders.
Adaptimmune Receives Transfer of IND for Lete-cel Program
Nov 29, 2023 · IGNYTE-ESO is a Phase 2, open-label trial for people with advanced synovial sarcoma or MRCLS to evaluate the efficacy, safety, and tolerability of lete-cel. Lete-cel's engineered TCR T-cells target NY-ESO-1+ tumors.
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical …
Aug 13, 2024 · The IGNYTE-3 trial (NCT06264180) will enroll 400 patients and evaluate RP1 plus nivolumab versus a defined list of physician’s choice treatment options, in patients with advanced melanoma who...